PROMISING PROGRESS: Improving Knowledge of Emerging Treatments in Advanced Pancreatic Cancer

PROMISING PROGRESS:  Improving Knowledge of Emerging Treatments in Advanced Pancreatic Cancer
PROMISING PROGRESS: Improving Knowledge of Emerging Treatments in Advanced Pancreatic Cancer
CME, CNE
James L. Abbruzzese, MD, FACP, FASCO; Andrew H. Ko, MD; Philip A. Philip, MD, PHD, FRCP
Release Date: February 01, 2016
Expiration Date: February 01, 2017
Pancreatic cancer (PC) is associated with the lowest survival rate of any major cancer: not only are there few screening tools that can accurately identify PC in an unselected population, but neither clinical examination nor serological markers are effective for early detection. Pancreatic cancer is also inherently resistant to most available treatments. However, the emerging recognition of the pancreatic cancer microenvironment, including the particularly abundant stroma, is playing a key role in understanding disease progression and resistance to chemotherapy. Today, two new front line therapies are shifting the treatment paradigm for the treatment of advanced metastatic pancreatic cancer. In this activity, faculty will discuss the latest research on the biology of metastatic pancreatic cancer, and how an understanding of this information can support improved individualized therapeutic strategies, both with today’s current treatment landscape and future therapeutic targets..

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE Expired
 

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved